5 Finnish University Hospitals Up Preparedness with New Technology Reports EpiGuard

EpiGuard reports all five University Hospitals in Finland come together to implement the new isolation and transport system. With EpiShuttles at all hospitals, Finland stands better prepared to face new pandemics or chemical and nuclear threats.

EpiGuard notes as one of the actions to increase Finland’s preparedness, the five university hospital districts jointly procured the so-called EpiShuttles, a Norwegian invention that isolates a contagious patient while being treated.

We are implementing a highly efficient tool to transport patients with highly contagious diseases, or chemical, biological or other contamination necessitating isolation. The single patient isolation and transport unit are designed to provide maximum public safety while allowing critical care and treatment to be performed on the contaminated patient inside. The unit can be used for patient transport through air, land, and sea in collaboration with the Finnish Border Guard and Defence Force units when needed, keeping society safe, Tom Silfvast, Chief Medical Officer at the Preparedness Unit at Helsinki University Hospital, said.

The procurement of the nine EpiShuttles is financed by the Government and steered by the Ministry of Social Affairs and Health. The new equipment will be used in all the areas that the five University Hospitals cover notes EpiGuard.

Ready for the next pandemic

Back in 2018, the WHO made a list of 10 diseases with the potential to cause a public health emergency. On that list was Disease X, a pathogen currently unknown. As it turns out, Disease X was the coronavirus. However, the threat of yet another new pathogen emerging, has never been greater.

With this new technology, we stand better prepared for a new pandemic. Contagious patient logistics are complicated. Finland has a lot of remote areas, and transporting contagious patients fast over long distances, into hospitals for treatment is a severe challenge. Time-consuming disinfection procedures of helicopters, aircraft, and ambulances after each transport threaten capacity. Not knowing what comes next, the EpiShuttle is our best option. We now stand ready to deploy if needed, Sanna Hoppu, Associate Professor and Chief Physician at Tampere University Hospital, said.

Safe transport of contagious patients is essential when handling the epidemic. The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation recommends such medical countermeasures as the EpiShuttle represents at a “Disease X dummy run”, the so-called Event 201.

Patient transport to where ICU capacity is available has proven to be a crucial piece of the puzzle when handling a pandemic. Only when safe transport is in place can we utilize the full capacity of the entire health care system and ensure treatment for everyone, Ellen Cathrine Andersen, CEO at EpiGuard said.

The WHO R&D Blueprint Special Advisory Group said, “History tells us that it is likely the next big outbreak will be something we have not seen before.” This still goes, and a Disease Y can surface at any time.

The UN Humanitarian Response Depot (UNHRD) holds six EpiShuttles, for the safe transport of contagious patients. Congo was the first place they dispatched, during the Ebola outbreak. UNHRD offers storage at no cost at six strategically located locations near major ports and airports.

EpiGuard notes their EpiShuttles are used by WHO as well as first responders in Germany, Belgium, Denmark, Peru, Ireland, Greece, Norway, and the UK. Also, national air forces like the British, Australian, Canadian, Danish, Norwegian and others are equipped with EpiShuttles. In the private sector, EpiShuttles are a common sight amongst companies like FAI air ambulance, Air Alliance Medflight, DRF Luftrettung, Keewatin Air, Luxembourg Air Rescue, Loganair and others.

SourceEpiGuard

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”